Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Retained Earnings (2020 - 2025)

Terns Pharmaceuticals filings provide 6 years of Retained Earnings readings, the most recent being -$517.7 million for Q4 2025.

  • Quarterly Retained Earnings fell 22.83% to -$517.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$517.7 million through Dec 2025, down 22.83% year-over-year, with the annual reading at -$517.7 million for FY2025, 22.83% down from the prior year.
  • Retained Earnings hit -$517.7 million in Q4 2025 for Terns Pharmaceuticals, down from -$494.1 million in the prior quarter.
  • Across five years, Retained Earnings topped out at $160000.0 in Q3 2024 and bottomed at -$517.7 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$214.4 million, with a median of -$218.2 million recorded in 2022.
  • The largest annual shift saw Retained Earnings skyrocketed 100.05% in 2024 before it crashed 308923.12% in 2025.
  • Terns Pharmaceuticals' Retained Earnings stood at -$182.1 million in 2021, then tumbled by 33.14% to -$242.4 million in 2022, then plummeted by 37.21% to -$332.6 million in 2023, then dropped by 26.71% to -$421.5 million in 2024, then fell by 22.83% to -$517.7 million in 2025.
  • Per Business Quant, the three most recent readings for TERN's Retained Earnings are -$517.7 million (Q4 2025), -$494.1 million (Q3 2025), and -$469.5 million (Q2 2025).